Imbioray (Hangzhou) Biomedicine Co., Ltd.

This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.

Ia期主要研究目的 1）评估复发/难治CD20阳性B细胞非霍奇金淋巴瘤受试者接受研究药物治疗的安全性和耐受性。 2）确定复发/难治CD20阳性B细胞非霍奇金淋巴瘤受试者接受研究药物治疗的推荐的II期剂量。 Ia期次要研究目的 1）初步评估复发/难治CD20阳性B细胞非霍奇金淋巴瘤受试者接受研究药物治疗的疗效。 2）IBR900细胞注射液在复发/难治CD20阳性B细胞非霍奇金淋巴瘤受试者中的药代动力学（PK）特征。

This is an open label clinical study: Phase Ia is a dose escalation phase, evaluating the safety, tolerability, RP2D, PK characteristics, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory B-cell non Hodgkin lymphoma (NHL); Phase Ib is the dose expansion stage, which is divided into two parts: monotherapy expansion (queue 1) and combination expansion (queue 2). The monotherapy expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma, while the combination expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection combined with CD20 monoclonal antibodies in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma.